Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182970 | 0.83 | TGFBR1 (0.42) | TGFBR1ACVR1B | |
| SCHEMBL6832626 | 0.82 | TGFBR1 (0.40) | TGFBR1CBFB | |
| Gw679410X SCHEMBL376414 | 0.80 | TGFBR1 (0.63) | TGFBR1ACVR1B | |
| Gw682841X SCHEMBL412218 | 0.79 | TGFBR1 (0.61) | TGFBR1ACVR1B | |
| SCHEMBL6180369 | 0.78 | TGFBR1 (0.59) | TGFBR1ACVR1B | |
| SCHEMBL154508 | 0.77 | TGFBR1 (0.56) | TGFBR1 | |
| SCHEMBL29504110 | 0.77 | TGFBR1 (0.56) | TGFBR1 | |
| SCHEMBL410420 | 0.76 | TGFBR1 (0.67) | TGFBR1ACVR1B | |
| SCHEMBL373364 | 0.76 | TGFBR1 (0.70) | TGFBR1ACVR1B | |
| SCHEMBL6178618 | 0.76 | TGFBR1 (0.59) | TGFBR1ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | claimed |
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885ACVR1B 15/4885CBFB 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.